Latest Administration News

Openn Negotiation Ltd remains under a Deed of Company Arrangement with no operational activity during the September quarter, focusing on recapitalisation efforts following insolvency and voluntary administration.

Openn Negotiation Ltd has entered voluntary administration following a failed $2.5 million capital raise, with its shares suspended on the ASX. Administrators have secured funding to maintain operations while pursuing a sale or recapitalisation.

Metallium Ltd has completed a A$50 million institutional raise, secured a Texas site, and validated its commercial Flash Joule Heating reactor, setting the stage for its first U.S. metals recovery plant commissioning by year-end 2025.

Vinyl Group Ltd reports a 17% quarterly increase in cash receipts to $3.786 million, driven by acquisitions and platform growth, while targeting cash-flow breakeven by Q2 FY26 through operational efficiencies and margin improvements.

IDT Australia has signed a memorandum with NASDAQ-listed Gelteq to establish a dedicated gel-based product manufacturing facility, marking a strategic expansion in pharmaceutical delivery technologies.

Visionflex Group Limited reported a positive operating cash flow for the June 2025 quarter alongside revised convertible note facilities with key investors, signaling steady liquidity and funding stability.

Imugene Limited has launched a $37.5 million equity raising through a Placement and Share Purchase Plan, offering new shares and options to fund its pivotal azer-cel clinical program. The raise includes attaching and piggyback options, subject to shareholder approval, aiming to bolster the company’s immuno-oncology pipeline.

Alliance Nickel has strengthened its financial position with an additional A$1.2 million unsecured loan and extended existing facilities, while reaffirming the commercial viability of its NiWest Nickel-Cobalt Project through a comprehensive Definitive Feasibility Study.

Prescient Therapeutics has initiated its first US clinical site for the PTX-100 Phase 2a trial targeting Cutaneous T-Cell Lymphoma, marking a key milestone in expanding patient recruitment beyond Australia.

Imagion Biosystems has received encouraging feedback from the FDA on its MagSense HER2 breast cancer imaging program, clearing the path for a Phase 2 clinical trial and fast-tracking manufacturing.

Prescient Therapeutics has extended its Share Purchase Plan closing date to 22 July 2025, aiming to raise up to A$7 million to advance its targeted cancer therapy PTX-100 through Phase 2 clinical trials.

HUB24 Limited has reported a record $19.8 billion in net inflows for FY25, driven by strong platform growth and significant migrations from Equity Trustees. The company also launched an innovative high net worth solution, reinforcing its market leadership.